CDK7 inhibitors have exhibited promising potency for tumor treatment, among which CT7001, SY-1365, and SY-5609 have undergone clinical trials (NCT03363893, NCT03134638, and NCT04247126).15,16. The gene discussed is CDK7; the disease is neoplasm.